V116 (21-Valent Pneumococcal Vaccine)
Pneumococcal Disease in Adults
SponsorMerck (MSD)
6,400Enrollment Target
180Trial Sites
5Countries
June 2026Est. Completion
About This Trial
Next-generation pneumococcal vaccine covering 8 unique serotypes not in current vaccines.
Primary Endpoints
- Opsonophagocytic activity
- IgG geometric mean concentrations
Latest Update
February 2026
Met all primary endpoints. BLA submitted to FDA; approval expected H2 2026.